Strong and persistent CD4+ T-cell response in healthy adults immunized with a candidate HIV-1 vaccine containing gp120, Nef and Tat antigens formulated in three Adjuvant Systems

Vaccine

Volumn 28, Issue 43, 2010, Pages 7016-7024

  Leroux Roels, Isabel ^a   Koutsoukos, Marguerite ^b   Clement, Frédéric ^a   Steyaert, Sophia ^a   Janssens, Michel ^b   Bourguignon, Patricia ^b   Cohen, Kristen ^c,d   Altfeld, Marcus ^c,d   Vandepapelière, Pierre ^b   Pedneault, Louise ^b   McNally, Lisa ^b   Leroux Roels, Geert ^a   Voss, Gerald ^b  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Adjuvant; CD4+ T cell response; HIV 1 vaccine; Human immunodeficiency virus

Indexed keywords

GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 2; NEF PROTEIN; NEUTRALIZING ANTIBODY; TRANSACTIVATOR PROTEIN;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG INDUCED HEADACHE; DRUG SAFETY; FATIGUE; FEMALE; FEVER; FOLLOW UP; HUMAN; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; MALE; MYALGIA; NAUSEA; NORMAL HUMAN; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOMITING;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; AIDS VACCINES; ANTIBODIES, NEUTRALIZING; CD4-POSITIVE T-LYMPHOCYTES; CROSS REACTIONS; DOUBLE-BLIND METHOD; FEMALE; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, CELLULAR; INTERLEUKIN-2; MALE; MIDDLE AGED; NEF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; YOUNG ADULT;

EID: 77957357557     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.08.035     Document Type: Article

References (60)

1. UNAIDS AIDS epidemic update: November 2009 2009, Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organisation (WHO), Geneva, Switzerland.
2. Berkley S.F., Koff W.C. Scientific and policy challenges to development of an AIDS vaccine. Lancet 2007, 370(9581):94-101.
3. Burton D.R., Desrosiers R.C., Doms R.W., Koff W.C., Kwong P.D., Moore J.P., et al. HIV vaccine design and the neutralizing antibody problem. Nat Immunol 2004, 5(3):233-236.
4. Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., Kaewkungwal J., Chiu J., Paris R., et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009, 361(23):2209-2220.
5. Walker C.M., Moody D.J., Stites D.P., Levy J.A. CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication. Science 1986, 234(4783):1563-1566.
6. Borrow P., Lewicki H., Hahn B.H., Shaw G.M., Oldstone M.B. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994, 68(9):6103-6110.
7. Koup R.A., Safrit J.T., Cao Y., Andrews C.A., McLeod G., Borkowsky W., et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994, 68(7):4650-4655.
8. Yang O.O., Kalams S.A., Trocha A., Cao H., Luster A., Johnson R.P., et al. Suppression of human immunodeficiency virus type 1 replication by CD8+ cells: evidence for HLA class I-restricted triggering of cytolytic and noncytolytic mechanisms. J Virol 1997, 71(4):3120-3128.
9. Jin X., Bauer D.E., Tuttleton S.E., Lewin S., Gettie A., Blanchard J., et al. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med 1999, 189(6):991-998.
10. Schmitz J.E., Kuroda M.J., Santra S., Sasseville V.G., Simon M.A., Lifton M.A., et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 1999, 283(5403):857-860.
11. Streeck H., Jolin J.S., Yassine-Diab B., Johnson R.C., Kwon D.S., Addo M.M., et al. HIV-1-specific CD8+ T cell responses during primary infection are major determinants of the viral set point and loss of CD4+ T cells. J Virol 2009, 83(15):7641-7648.
12. Buchbinder S.P., Mehrotra D.V., Duerr A., Fitzgerald D.W., Mogg R., Li D., et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008, 372(9653):1881-1893.
13. Betts M.R., Nason M.C., West S.M., De Rosa S.C., Migueles S.A., Abraham J., et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 2006, 107(12):4781-4789.
14. Bourgeois C., Veiga-Fernandes H., Joret A.M., Rocha B., Tanchot C. CD8 lethargy in the absence of CD4 help. Eur J Immunol 2002, 32(8):2199-2207.
15. Janssen E.M., Lemmens E.E., Wolfe T., Christen U., von Herrath M.G., Schoenberger S.P. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 2003, 421(6925):852-856.
16. Shedlock D.J., Shen H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 2003, 300(5617):337-339.
17. Sun J.C., Bevan M.J. Defective CD8 T cell memory following acute infection without CD4 T cell help. Science 2003, 300(5617):339-342.
18. + T cells. J Exp Med 2004, 200(6):701-712.
19. Sun J.C., Williams M.A., Bevan M.J. CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection. Nat Immunol 2004, 5(9):927-933.
20. Letvin N.L., Mascola J.R., Sun Y., Gorgone D.A., Buzby A.P., Xu L., et al. Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys. Science 2006, 312(5779):1530-1533.
21. Sun Y., Schmitz J.E., Buzby A.P., Barker B.R., Rao S.S., Xu L., et al. Virus-specific cellular immune correlates of survival in vaccinated monkeys after simian immunodeficiency virus challenge. J Virol 2006, 80(22):10950-10956.
22. Yang T.C., Millqar J., Groves T., Zhou W., Grinshtein N., Parsons R., et al. On the role of CD4+ T cells in the CD8+ T-cell response elicited by recombinant adenovirus vaccines. Mol Ther 2007, 15(5):997-1006.
23. Kannanganat S., Kapogiannis B.G., Ibegbu C., Chennareddi L., Goepfert P., Robinson H.L., et al. Human immunodeficiency virus type 1 controllers but not noncontrollers maintain CD4 T cells coexpressing three cytokines. J Virol 2007, 81(21):12071-12076.
24. Potter S.J., Lacabaratz C., Lambotte O., Perez-Patrigeon S., Vingert B., Sinet M., et al. Preserved central memory and activated effector memory CD4+ T-cell subsets in human immunodeficiency virus controllers: an ANRS EP36 study. J Virol 2007, 81(24):13904-13915.
25. Aguilar J.C., Rodriguez E.G. Vaccine adjuvants revisited. Vaccine 2007, 25(19):3752-3762.
26. Garçon N., Chomez P., Van Mechelen M. GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines 2007, 6(5):723-739.
27. Vandepapelière P., Rehermann B., Koutsoukos M., Moris P., Garçon N., Wettendorff M., et al. Potent enhancement of cellular and humoral immune responses against recombinant hepatitis B antigens using AS02A adjuvant in healthy adults. Vaccine 2005, 23(20):2591-2601.
28. Stoute J.A., Slaoui M., Heppner D.G., Momin P., Kester K.E., Desmons P., et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. N Engl J Med 1997, 336(2):86-91.
29. Alonso P.L., Sacarlal J., Aponte J.J., Leach A., Macete E., Milman J., et al. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 2004, 364(9443):1411-1420.
30. Kester K.E., Cummings J.F., Ofori-Anyinam O., Ockenhouse C.F., Krzych U., Moris P., et al. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J Infect Dis 2009, 200(3):337-346.
31. Voss G., Manson K., Montefiori D., Watkins D.I., Heeney J., Wyand M., et al. Prevention of disease induced by a partially heterologous AIDS virus in rhesus monkeys by using an adjuvanted multicomponent protein vaccine. J Virol 2003, 77(2):1049-1058.
32. Goepfert P.A., Tomaras G.D., Horton H., Montefiori D., Ferrari G., Deers M., et al. Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers. Vaccine 2007, 25(3):510-518.
33. Desombere I., Hauser P., Rossau R., Paradijs J., Leroux-Roels G. Nonresponders to hepatitis B vaccine can present envelope particles to T lymphocytes. J Immunol 1995, 154(2):520-529.
34. Vandepapelière P., Van Mechelen M., Garçon N., Moris P., Janssens M., Koutsoukos M., et al. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers. Vaccine 2008, 26(10):1375-1386.
35. Suni M.A., Picker L.J., Maino V.C. Detection of antigen-specific T cell cytokine expression in whole blood by flow cytometry. J Immunol Methods 1998, 212(1):89-98.
36. Rodbard D., Frazier G.R. Statistical analysis of radioligand assay data. Methods Enzymol 1975, 37:3-22.
37. Karpinski K.F., Hayward S., Tryphonas H. Statistical considerations in the quantitation of serum immunoglobulin levels using the enzyme-linked immunosorbent assay (ELISA). J Immunol Methods 1987, 103(2):189-194.
38. Richman D.D., Wrin T., Little S.J., Petropoulos C.J. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci USA 2003, 100(7):4144-4149.
39. Schweighardt B., Liu Y., Huang W., Chappey C., Lie Y.S., Petropoulos C.J., et al. Development of an HIV-1 reference panel of subtype B envelope clones isolated from the plasma of recently infected individuals. J Acquir Immune Defic Syndr 2007, 46(1):1-11.
40. Li M., Gao F., Mascola J.R., Polonis V.R., Koutsoukos M., Voss G., et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 2005, 79(16):10108-10125.
41. Forgus S., Leroux-Roels I., De Boever F., Leroux-Roels G., Ofori-Anyinam O., Moris P., et al. Safety and immunogenicity of the M72/AS01B and M72/AS02A candidate tuberculosis vaccines in PPD-negative Belgian adults. TBV 2008-TB vaccines for the World 2008.
42. Duerr A., Wasserheit J.N., Corey L. HIV vaccines: new frontiers in vaccine development. Clin Infect Dis 2006, 43(4):500-511.
43. McHeyzer-Williams L.J., Pelletier N., Mark L., Fazilleau N., McHeyzer-Williams M.G. Follicular helper T cells as cognate regulators of B cell immunity. Curr Opin Immunol 2009, 21(3):266-273.
44. Hsu S.M., Cossman J., Jaffe E.S. Lymphocyte subsets in normal human lymphoid tissues. Am J Clin Pathol 1983, 80(1):21-30.
45. Liu Y.J., Joshua D.E., Williams G.T., Smith C.A., Gordon J., MacLennan I.C. Mechanism of antigen-driven selection in germinal centres. Nature 1989, 342(6252):929-931.
46. Linterman M.A., Vinuesa C.G. Signals that influence T follicular helper cell differentiation and function. Semin Immunopathol 2010, 32(2):183-196.
47. Fazilleau N., McHeyzer-Williams L.J., Rosen H., McHeyzer-Williams M.G. The function of follicular helper T cells is regulated by the strength of T cell antigen receptor binding. Nat Immunol 2009, 10(4):375-384.
48. Rosenberg E.S., Altfeld M., Poon S.H., Phillips M.N., Wilkes B.M., Eldridge R.L., et al. Immune control of HIV-1 after early treatment of acute infection. Nature 2000, 407(6803):523-526.
49. Douek D.C., Brenchley J.M., Betts M.R., Ambrozak D.R., Hill B.J., Okamoto Y., et al. HIV preferentially infects HIV-specific CD4+ T cells. Nature 2002, 417(6884):95-98.
50. Schnittman S.M., Greenhouse J.J., Psallidopoulos M.C., Baseler M., Salzman N.P., Fauci A.S., et al. Increasing viral burden in CD4+ T cells from patients with human immunodeficiency virus (HIV) infection reflects rapidly progressive immunosuppression and clinical disease. Ann Intern Med 1990, 113(6):438-443.
51. Connor R.I., Mohri H., Cao Y., Ho D.D. Increased viral burden and cytopathicity correlate temporally with CD4+ T-lymphocyte decline and clinical progression in human immunodeficiency virus type 1-infected individuals. J Virol 1993, 67(4):1772-1777.
52. + T cell responses associated with control of viremia. Science 1997, 278(5342):1447-1450.
53. Day C.L., Walker B.D. Progress in defining CD4 helper cell responses in chronic viral infections. J Exp Med 2003, 198(12):1773-1777.
54. Younes S.A., Yassine-Diab B., Dumont A.R., Boulassel M.R., Grossman Z., Routy J.P., et al. HIV-1 viremia prevents the establishment of interleukin 2-producing HIV-specific memory CD4+ T cells endowed with proliferative capacity. J Exp Med 2003, 198(12):1909-1922.
55. Streeck H., Schweighardt B., Jessen H., Allgaier R.L., Wrin T., Stawiski E.W., et al. Loss of HIV-1-specific T-cell responses associated with very rapid HIV-1 disease progression. AIDS 2007, 21(7):889-891.
56. McMichael A., Mwau M., Hanke T. HIV T cell vaccines, the importance of clades. Vaccine 2002, 20(15):1918-1921.
57. Johnston M.I., Fauci A.S. An HIV vaccine-evolving concepts. N Engl J Med 2007, 356(20):2073-2081.
58. Montefiori D., Sattentau Q., Flores J., Esparza J., Mascola J. Antibody-based HIV-1 vaccines: recent developments and future directions. PLoS Med 2007, 4(12):e348. Working Group convened by the Global HIV Vaccine Enterprise.
59. Coplan P.M., Gupta S.B., Dubey S.A., Pitisuttithum P., Nikas A., Mbewe B., et al. Cross-reactivity of anti-HIV-1 T cell immune responses among the major HIV-1 clades in HIV-1-positive individuals from 4 continents. J Infect Dis 2005, 191(9):1427-1434.
60. Osmanov S., Pattou C., Walker N., Schwardlander B., Esparza J. Estimated global distribution and regional spread of HIV-1 genetic subtypes in the year 2000. J Acquir Immune Defic Syndr 2002, 29(2):184-190. WHO-UNAIDS Network for HIV Isolation and Characterization.